UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1142-11
Program Prior Authorization/Notification
Medications Ruconest® (C1 esterase inhibitor [recombinant])
P&T Approval Date 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021,
7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Ruconest (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in
adult and adolescent patients with hereditary angioedema (HAE). Effectiveness was not
established in HAE patients with laryngeal attacks.1
2. Coverage Criteriaa:
A. Ruconest will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. For the treatment of acute HAE attacks
-AND-
3. Not used in combination with other products indicated for acute HAE attacks (e.g.,
Berinert, Firazyr, or Kalbitor)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limitations may be in place.
4. References:
1. Ruconest [package insert]. Bridgewater, NJ: Pharming Healthcare, Inc.; April 2020
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Ruconest (C1 esterase inhibitor
[recombinant])
Change Control
8/2014 New program.
8/2015 Annual review. Updated references.
7/2016 Annual review with no changes to the coverage criteria. Updated
background and references.
7/2017 Annual review. No changes.
7/2018 Annual review. No changes to the coverage criteria. Updated
references.
7/2019 Annual review. No changes to the program.
7/2020 Annual review. No changes to coverage criteria.
7/2021 Annual review. No changes to coverage criteria.
7/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote. Updated reference.
7/2023 Annual review. Revised wording of criteria without change to clinical
intent.
7/2024 Annual review. No changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
2